International prospective evaluation of scintimammography with 99mTechnetium sestamibi

Sampalis, Fotini; Denis, Ronald; Picard, D; Fleiszer, David; Martin, G.; Nassif, Edgard; Sampalis, John S.

doi:10.1016/s0002-9610(03)00077-1

Cited by 39 publications

(11 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to older scintimammography studies, we performed BSGI with a dedicated small FOV gamma camera. 18 The development of these cameras increased the spatial resolution and enabled an exact spatial correlation of BSGI findings with MG.…”

Section: Discussionmentioning

confidence: 99%

“…For the ultrasound examination, we used high-end equipment (Voluson E8; GE Healthcare, Chalfont St Giles, UK, or Aixplorer® Expert Edition, SuperSonic, Aix-en Provence, France). Both breasts were examined using a high-frequency (12)(13)(14)(15)(16)(17)(18), high-resolution linear array transducer in radial and antiradial directions. All findings were documented in two perpendicular planes.…”

Section: Breast Ultrasoundmentioning

confidence: 99%

See 1 more Smart Citation

Added value of semi-quantitative breast-specific gamma imaging in the work-up of suspicious breast lesions compared to mammography, ultrasound and 3-T MRI

Meißnitzer¹,

Seymer²,

Keinrath³

et al. 2015

BJR

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Breast Ultrasoundmentioning

confidence: 99%

Added value of semi-quantitative breast-specific gamma imaging in the work-up of suspicious breast lesions compared to mammography, ultrasound and 3-T MRI

Meißnitzer¹,

Seymer²,

Keinrath³

et al. 2015

BJR

View full text Add to dashboard Cite

show abstract

“…There are considerable data regarding 99m Tc-sestamibi, a radionuclide imaging agent approved by the FDA for cardiac imaging and for its ability to detect breast cancers. 99m Tc-sestamibi has been shown to be promising in the detection of microcalcifications (Fondrinier et al, 2004), occult breast carcinomas (Coover et al, 2004), breast cancer (Sampalis et al, 2003), as well as in staging, axillary lymph node evaluation (Myslivecek et al, 2004; Ozulker et al, 2010; Zhou et al, 2009) and sentinel node mapping (Arcan et al, 2005; Sadeghi et al, 2010). Although 99m Tc-sestamibi is approved by the FDA for breast imaging, current evidence does not support its use for breast cancer screening [NCCN guidelines v2 2011], in part due to the difficulty of detecting lesions smaller than 10 mm.…”

Section: Imaging Drug Uptake and Accumulation In Tissues And In Tumentioning

confidence: 99%

Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studies

Amiri‐Kordestani

Basseville

Kurdziel

et al. 2012

Drug Resistance Updates

191

128

View full text Add to dashboard Cite

This special issue of Drug Resistance Updates is dedicated to multidrug resistance protein 1 (MDR-1), 35 years after its discovery. While enormous progress has been made and our understanding of drug resistance has become more sophisticated and nuanced, after 35 years the role of MDR-1 in clinical oncology remains a work in progress. Despite clear in vitro evidence that P-glycoprotein (Pgp), encoded by MDR-1, is able to dramatically reduce drug concentrations in cultured cells, and that drug accumulation can be increased by small molecule inhibitors, clinical trials testing this paradigm have mostly failed. Some have argued that it is no longer worthy of study. However, repeated analyses have demonstrated MDR-1 expression in a tumor is a poor prognostic indicator leading some to conclude MDR-1 is a marker of a more aggressive phenotype, rather than a mechanism of drug resistance. In this review we will re-evaluate the MDR-1 story in light of our new understanding of molecular targeted therapy, using breast and lung cancer as examples. In the end we will reconcile the data available and the knowledge gained in support of a thesis that we understand far more than we realize, and that we can use this knowledge to improve future therapies.

show abstract

“…The overall sensitivity reported included palpable and impalpable lesions, which likely explains the difference in reported results in this and other reviews (32). In a multicenter study to assess the effectiveness of breast scintigraphy with 99mTc-sestamibi in 1243 women with 33% palpable lesions, Sampalis et al (33) concluded that breast scintigraphy was highly effective and potentially useful as a complement to mammography for the early detection of breast cancer. These authors reported a sensitivity and specificity of 93% and 87%, respectively, with a negative predictive value of 98% and a positive predictive value of 58% (33).…”

Section: Discussionmentioning

confidence: 99%

99mTc-thymine scintigraphy may be a promising method in the diagnosis of breast cancer

Ribeiro

Souza

Lopes

et al. 2013

Clinics

View full text Add to dashboard Cite

OBJECTIVE:Mammography has been established as the gold standard for the detection of breast cancer, and imaging techniques such as ultrasonography, magnetic resonance imaging, scintigraphy and positron emission tomography may be useful to improve its sensitivity and specificity. The objective of this study with breast scintigraphy was to evaluate the uptake of 99mTc-thymine in mammary lesions.METHODS:A total of 45 patients were included in this study. Thirty-three patients (73%) were subjected to surgery or percutaneous biopsy, providing histopathological data. The other 12 patients who remained under surveillance received clinical examinations and biannual mammography with a normal follow-up of at least three years, the data from which were used for comparison with the scintimammography results.RESULTS:The majority of patients (64.4%) had clinically impalpable lesions with a mammogram diagnosis of microcalcifications, impalpable nodules, or focal asymmetry. Of the studied lesions, 87% were smaller or equal to 20 mm in diameter, and 22% had malignant histopathological findings. Scintigraphy with 99mTc-thymine had a sensitivity of 70%, a specificity of 85.7%, positive and negative predictive values of 58.3% and 90.9%, respectively, and an accuracy of 82.2%.CONCLUSIONS:The results of this study are consistent with those previously reported by other authors. The good specificity and high negative predictive value of this technique and the absence of uptake in the heart indicate that it may be a promising complementary method in clinical practice and that it may contribute to reducing unnecessary benign biopsies.

show abstract

International prospective evaluation of scintimammography with 99mTechnetium sestamibi

Cited by 39 publications

References 16 publications

Added value of semi-quantitative breast-specific gamma imaging in the work-up of suspicious breast lesions compared to mammography, ultrasound and 3-T MRI

Added value of semi-quantitative breast-specific gamma imaging in the work-up of suspicious breast lesions compared to mammography, ultrasound and 3-T MRI

Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studies

99mTc-thymine scintigraphy may be a promising method in the diagnosis of breast cancer

Contact Info

Product

Resources

About